Fig. 5: Low-dose TM and 2-DG preconditioning enhances cisplatin resistance. | Cell Death & Disease

Fig. 5: Low-dose TM and 2-DG preconditioning enhances cisplatin resistance.

From: Tolerable glycometabolic stress boosts cancer cell resilience through altered N-glycosylation and Notch signaling activation

Fig. 5

A Cisplatin-induced apoptosis in HA-low Has2+Neo and HA-high Has2ΔNeo cells. Has2ΔNeo and Has2+Neo cells were treated with 0-50 µM cisplatin for 16 h. After staining with fluorescent Annexin V and PI, apoptotic cells were analyzed by flow cytometry. Early and late apoptotic cells were represented as Annexin V+/PI- and Annexin V+/PI+ subpopulations, respectively. Data are the mean ± SD from n = 4. Two-tailed Student’s t-test. *p < 0.05, **p < 0.01. B, C Cisplatin-induced apoptosis in Has2+Neo cells pretreated with low-dose TM or 2-DG. HA-low Has2+Neo cells were treated with 0.1 μg/ml TM (B) or 0.1 mM 2-DG (C) for 8 days. Before staining with fluorescent Annexin V and PI, the cells were treated with 0-50 µM cisplatin for 16 h. Data are mean ± SD from n = 8 for (B) and n = 4 for (C). Two-tailed Student’s t-test. *p < 0.05, **p < 0.01.

Back to article page